Seattle Genetics Stock News

Here are some of the most active stocks in the premarket on Monday. U.S. stock futures ES00, +0.50% were pointing to an advance after the worst week for the S&P 500 SPX, -1.05% since the period that e

The deal would strengthen Pfizer's lineup of cancer treatments, The Wall Street Journal reports.

Pfizer Inc is in early talks to acquire drugmaker Seagen Inc , the Wall Street Journal reported late on Sunday, citing people familiar with the matter.

Pfizer Inc. is in talks to acquire biotech Seagen Inc, according to people familiar with the matter, the latest potential deal for a big drug company aimed at adding a promising class of targeted canc

Investors and analysts liked what they heard in the company's Q4 update.

Seagen (SGEN) reports better-than-expected results in the fourth quarter of 2022, beating both earnings and sales estimates. Stock up in the after-market hours in response to the news.

Seagen Inc. (NASDAQ:SGEN ) Q4 2022 Results Conference Call February 15, 2023 4:30 PM ET Company Participants Doug Maffei - VP, IR David Epstein - CEO Chip Romp - EVP, Commercial U.S. Todd Simpson - CF

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 21.57% and 9.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.

The FDA grants accelerated approval to Seagen's (SGEN) Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer.

BOTHELL, Wash.--( BUSINESS WIRE )--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 after the clos

Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business

William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period. Seagen Inc.'s (NASD

SGEN has been under pressure since a rumored takeover deal by pharmaceutical giant Merck & Co. fell through last summer. The company last reported its Q3 earnings with stronger than expected sales, wi

Merck (MRK) and Seagen's (SGEN) sBLAs seek approval of Padcev plus Keytruda for locally advanced or metastatic urothelial cancer in patients who are not eligible for cisplatin-containing chemotherapy.